311 related articles for article (PubMed ID: 24084477)
21. The effect of adding psychodynamic therapy to antidepressants in patients with major depressive disorder. A systematic review of randomized clinical trials with meta-analyses and trial sequential analyses.
Jakobsen JC; Hansen JL; Simonsen E; Gluud C
J Affect Disord; 2012 Mar; 137(1-3):4-14. PubMed ID: 21501877
[TBL] [Abstract][Full Text] [Related]
22. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
Papakostas GI; Martinson MA; Fava M; Iovieno N
J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
Ma D; Zhang Z; Zhang X; Li L
Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
[TBL] [Abstract][Full Text] [Related]
24. The effect of CBT and its modifications for relapse prevention in major depressive disorder: a systematic review and meta-analysis.
Zhang Z; Zhang L; Zhang G; Jin J; Zheng Z
BMC Psychiatry; 2018 Feb; 18(1):50. PubMed ID: 29475431
[TBL] [Abstract][Full Text] [Related]
25. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication.
Parikh SV; Segal ZV; Grigoriadis S; Ravindran AV; Kennedy SH; Lam RW; Patten SB;
J Affect Disord; 2009 Oct; 117 Suppl 1():S15-25. PubMed ID: 19682749
[TBL] [Abstract][Full Text] [Related]
26. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years.
Zimmerman M; Holst CG; Clark HL; Multach M; Walsh E; Rosenstein LK; Gazarian D
CNS Drugs; 2016 Dec; 30(12):1209-1218. PubMed ID: 27541608
[TBL] [Abstract][Full Text] [Related]
27. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
28. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
29. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents (Review).
Gillies D; Taylor F; Gray C; O'Brien L; D'Abrew N
Evid Based Child Health; 2013 May; 8(3):1004-116. PubMed ID: 23877914
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of interventions for treatment resistant major depressive disorder in adolescents.
Boylan K; MacQueen G; Kirkpatrick R; Lee J; Santaguida PL
Eur Child Adolesc Psychiatry; 2020 Apr; 29(4):433-443. PubMed ID: 31165921
[TBL] [Abstract][Full Text] [Related]
31. Tachyphylaxis in major depressive disorder: A review of the current state of research.
Kinrys G; Gold AK; Pisano VD; Freeman MP; Papakostas GI; Mischoulon D; Nierenberg AA; Fava M
J Affect Disord; 2019 Feb; 245():488-497. PubMed ID: 30439676
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of psychotherapeutic interventions for women with metastatic breast cancer: Context matters.
Beatty L; Kemp E; Butow P; Girgis A; Schofield P; Turner J; Hulbert-Williams NJ; Levesque JV; Koczwara B
Psychooncology; 2018 Jan; 27(1):34-42. PubMed ID: 28432855
[TBL] [Abstract][Full Text] [Related]
33. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.
Iosifescu DV; Bankier B; Fava M
Curr Psychiatry Rep; 2004 Jun; 6(3):193-201. PubMed ID: 15142472
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and acceptability of adjunctive psychological and pharmacological interventions for treatment-resistant depression: protocol for a systematic review and network meta-analysis.
Husain MI; Strawbridge R; Carter B; Jones BDM; Young A; Carvalho AF
BMJ Open; 2019 May; 9(5):e028538. PubMed ID: 31092667
[TBL] [Abstract][Full Text] [Related]
35. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective.
Turner P; Kantaria R; Young AH
J Psychopharmacol; 2014 Feb; 28(2):85-98. PubMed ID: 24108407
[TBL] [Abstract][Full Text] [Related]
36. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review.
Brockbank J; Krause T; Moss E; Pedersen AM; Mørup MF; Ahdesmäki O; Vaughan J; Brodtkorb TH
Health Qual Life Outcomes; 2021 Mar; 19(1):94. PubMed ID: 33736649
[TBL] [Abstract][Full Text] [Related]
37. Continuity is the main challenge in treating major depressive disorder in psychiatric care.
Melartin TK; Rytsälä HJ; Leskelä US; Lestelä-Mielonen PS; Sokero TP; Isometsä ET
J Clin Psychiatry; 2005 Feb; 66(2):220-7. PubMed ID: 15705008
[TBL] [Abstract][Full Text] [Related]
38. Psychotherapy, antidepressants, and their combination for chronic major depressive disorder: a systematic review.
Spijker J; van Straten A; Bockting CL; Meeuwissen JA; van Balkom AJ
Can J Psychiatry; 2013 Jul; 58(7):386-92. PubMed ID: 23870720
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological and psychosocial treatment of depression in primary care: Low intensity and poor adherence and continuity.
Vuorilehto MS; Melartin TK; Riihimäki K; Isometsä ET
J Affect Disord; 2016 Sep; 202():145-52. PubMed ID: 27262636
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
